7/17/2009 | SS | Quigley board names chairman Karkus to top post, Cuddihy as COO
|
6/18/2009 | SS | Quigley names chairman Ted Karkus as interim chief executive officer
|
6/15/2009 | SS | Quigley gets new board after court ruling; Karkus elected chairman
|
6/1/2009 | SS | Quigley's board composition on hold despite final election results
|
5/19/2009 | SS | Quigley Pharma COO suspended on alleged financial deal with Karkus
|
5/19/2009 | SS | Market Commentary: Pepsi expected to up offers; SumTotal bidding war persists; Quigley prepares for investor vote
|
5/18/2009 | SS | Quigley to consider joint venture, possible sale of Pharma division
|
5/18/2009 | SS | Quigley shareholder claims victory in court ahead of Wednesday meeting
|
5/14/2009 | SP | Quigley shareholder pushes for change, new board members on Wednesday
|
5/12/2009 | SS | Quigley's slate receives mixed support from two proxy advisory firms
|
5/7/2009 | SS | Quigley urges shareholders to reject Ted Karkus' dissident slate
|
5/1/2009 | SS | Quigley shareholder seeks support for dissident slate of nominees
|
4/15/2009 | SS | Quigley shareholder seeks support for dissident slate of nominees
|
4/9/2009 | SS | Quigley shareholder nominates seven to replace board of directors
|
4/6/2009 | SS | Quigley investor wants to replace company's entire board
|
9/26/2006 | BT | Quigley says QR-333 data promising for diabetic neuropathy
|
8/21/2006 | BT | Quigley gets patent covering peripheral neural, vascular complaints for diabetic neuropathy drug QR-333
|
8/8/2006 | BT | Quigley says QR-443 treats 75% of animal subjects in muscle-wasting trial
|
5/22/2006 | BT | Quigley plans additional studies of QR-435 for ocular herpes
|
5/9/2006 | BT | Quigley Pharma screens patients for study of QR-333 in diabetic peripheral neuropathy
|
4/10/2006 | BT | Quigley gets IND number, will begin testing drug for diabetic peripheral neuropathy
|
3/7/2006 | BT | Quigley files IND for QR-333 diabetic topical compound
|
1/31/2006 | BT | Quigley to study anti-inflammatory compound QR-440 in arthritic dogs
|
12/9/2005 | BT | Quigley Pharma's QR-442 delays onset of multiple sclerosis in mice, study says
|
12/8/2005 | BT | Quigley Pharma's QR-336 protects mice from lethal radiation, study shows
|
12/1/2005 | BT | Quigley's QR-441 compound blocks, deactivates flu virus in face masks
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|